A patient being treated with Aduro Biotech's (Nasdaq: ADRO) CRS-207 developed listeriosis. The stock price plunged $5.09 to $27.14.
Aduro Biotech patient develops listeriosis
November 24, 2015 at 12:04 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|